DUBLIN, Ohio, July 11, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced the launch of the Cardinal Health™ One Voice Initiative for pharmacy advocacy, which provides direct financial assistance to state pharmacy associations for the purpose of supporting independent pharmacists' advocacy efforts.  This investment furthers Cardinal Health's longstanding advocacy around the future of independent pharmacies and ongoing partnerships with industry organizations to support pharmacists' efforts to ...

The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.What Are Smart Beta ETFs?Products that are based on market cap weighted indexes, which are strategies designed to reflect a specific market segment or the market as a whole, have traditionally dominated the ETF industry.Market cap weighted indexes work great for investors who believe in market efficiency. They provide a low ...

WATCH: Trump Floats 200% Tariffs On Pharmaceuticals–Here's What To Know https://t.co/Bc8nEyBz0k ...

We'll be announcing something very soon on pharmaceuticals. Uh we're going to give people about a year, a year and a half to come in and after that they're going to be tariffed. If they have to bring the pharmaceuticals into the country, the drugs and other things into the country, they're going to be tariffed at a very, very high rate, like 200%.We'll give them a certain period of time to get their act together. But they were all here. Now they all left.They went to other places because we allowed people t ...

Market Overview - Markets experienced mixed results with the S&P 500 declining by 0.7%, the Dow Jones Industrial Average down 0.4%, while the Russell 2000 gained 0.7% and the Nasdaq Composite remained flat [2][6] Tariff Announcements - President Trump announced a 50% tariff on copper imports effective August 1st, which led to a 13% increase in copper futures, closing at an all-time high of $5.6450 [3][5] - In addition to copper, Trump is considering tariffs on pharmaceuticals of up to 200% to encourage relocation of supply chains to the U.S. [5] - BRIC nations will face an additional 10% tariff if they align with "anti-American policies," although specifics were not defined [5] Economic Implications - Copper is a critical commodity, widely used in construction and consumer goods, and its price movements are often seen as indicators of economic health, particularly in relation to inflation and recession risks [4] - The Federal Reserve's upcoming decisions on interest rates may be influenced by the recent tariff announcements, as they introduce uncertainty into economic modeling [7] Company Performance - Nvidia shares reached a record high of $160, indicating strength in the tech sector [6] - Conversely, Amazon's shares fell nearly 2% as Prime Days commenced, reflecting some weakness in the retail sector [6] Upcoming Earnings - Delta Airlines is set to report earnings, with strong summer travel expected to be a focal point [9] - Microsoft received an upgrade from Oppenheimer with a price target of $600, although current trading around $500 suggests potential challenges in reaching that target [9]

Trump Floats 200% Tariffs On Pharmaceuticals https://t.co/6HJGOY7BUK ...

And we'll be announcing something very soon on pharmaceuticals. We're going to give people about a year, a year and a half to come in. And after that, they're going to be tariffed. If they have to bring the pharmaceuticals into the country, the drugs and other things into the country, they're going to be tariffed at a very, very high rate, like 200%.We'll give them a certain period of time to get their act together. But they were all here. Now, they all left.They went to other places because we allowed peop ...

We're going to be announcing pharmaceuticals, chips, uh, and various couple of other things, you know, big ones. We did steel, as you know, they're 50%. We did aluminum, 50%, lumber just came out.I'm sure that's copper. And we did cars. Cars.And now today we're doing copper. Copper. What would that t be on the second.Uh, I believe the tariff on copper, we're going to make it 50%. Uh 50%. ...

We'll be announcing something very soon on pharmaceuticals. We're going to give people about a year, year and a half to come in. And after that, they're going to be terrified if they have to bring the pharmaceuticals into the country, the drugs and other things into the country. They're going to be terrified at a very, very high rate, like 200%.We'll give them a certain period of time to get their act together. But they were all here now. They all left.They went to other places because we allowed people tha ...

Core Viewpoint - President Trump has threatened to impose tariffs of up to 200% on imported pharmaceuticals, indicating a significant shift in trade policy that could impact the pharmaceutical industry in the U.S. [1][2] Group 1: Tariff Announcement - The proposed tariffs would be set at a very high rate, potentially reaching 200% [1] - Trump mentioned that there would be a grace period of about one to one and a half years for drugmakers to adjust before the tariffs take effect [2] - This announcement marks Trump's most significant comment on pharmaceutical tariffs since the initiation of a Section 232 investigation in April [3] Group 2: Industry Impact - The planned tariffs are expected to negatively affect pharmaceutical companies, which have warned that such levies could increase costs, deter investments in the U.S., and disrupt the drug supply chain, ultimately putting patients at risk [4] - The pharmaceutical industry is already facing challenges from Trump's drug pricing policies, which threaten their profitability and ability to invest in research and development [4] Group 3: Manufacturing Incentives - Trump has stated that the tariffs would encourage drug companies to relocate their manufacturing operations back to the U.S. [5] - Companies like Eli Lilly, Johnson & Johnson, and AbbVie are reportedly increasing their investments in the U.S. as domestic drug manufacturing has significantly declined over the past few decades [5]